» Articles » PMID: 7500467

Localization of the Alpha 1A-adrenoceptor in the Human Prostate

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 1995 Dec 1
PMID 7500467
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We determined the tissue localization of the alpha 1a-adrenoceptor in the human prostate.

Materials And Methods: Autoradiographic localization of the alpha 1a-adrenoceptor in the human prostate was determined by performing competitive displacement experiments on slide mounted tissue sections using the ligand 125iodine-2-(-[4-hydroxyphenyl]-ethyl-aminomethyl)tetralone (125I-Heat), and the alpha 1-antagonists WB-4101 (4 x 10(-8) M.) and 5-carboxamido-2,6-diethyl-1,4-dihydro-3-[N-(3-[4-hydroxy-4-phenylpipe ridin- yl]propyl)]carboxamido-4-(4-nitrophenyl) (SNAP 5272, 3 x 10(-7) M.). Under these experimental conditions, WB-4101 and SNAP 5272 are selective alpha 1a/alpha 1d-adrenoceptor and alpha 1a-adrenoceptor antagonists, respectively. The autoradiographs were quantitatively analyzed using a computer image analysis system.

Results: Specific 125I-Heat binding associated with the epithelium and stroma were independently analyzed. WB-4101 and SNAP 5272 inhibited 100% of the specific 125I-Heat binding in the stroma, suggesting that all of the stromal alpha 1-adrenoceptors are of the alpha 1a subtype. WB-4101 inhibited none of the specific 125I-Heat binding in the epithelium, suggesting that the alpha 1-adrenoceptor in the epithelium is of the alpha 1b subtype. SNAP 5272 displaced only 25% of the specific 125I-Heat binding in the epithelium, suggesting that a relatively small percentage of the epithelial alpha 1-adrenoceptor is of the alpha 1a subtype.

Conclusions: To our knowledge, our study represents the first cellular localization of the alpha 1-adrenoceptor subtypes in the human prostate using highly selective alpha 1-adrenoceptor antagonists and is consistent with the physiological observation that the activity of prostatic smooth muscle is mediated by the alpha 1a-adrenoceptor.

Citing Articles

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia.

Chung J, Choi S, Kim B, Kim T, Yoo E, Il Kim C Korean J Urol. 2011; 52(7):479-84.

PMID: 21860769 PMC: 3151636. DOI: 10.4111/kju.2011.52.7.479.


Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells.

Katsogiannou M, El Boustany C, Gackiere F, Delcourt P, Athias A, Mariot P PLoS One. 2009; 4(9):e7068.

PMID: 19763272 PMC: 2742726. DOI: 10.1371/journal.pone.0007068.


Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.

Kojima Y, Sasaki S, Hayashi Y, Tsujimoto G, Kohri K Nat Clin Pract Urol. 2009; 6(1):44-53.

PMID: 19132005 DOI: 10.1038/ncpuro1276.


Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study.

Park C, Chang H, Oh B, Kim H, Sul C, Chung S Clin Drug Investig. 2007; 24(1):41-7.

PMID: 17516689 DOI: 10.2165/00044011-200424010-00005.


alpha-Blocker Therapy: Current Update.

Kaplan S Rev Urol. 2006; 7 Suppl 8:S34-42.

PMID: 16985889 PMC: 1477635.